Status:
WITHDRAWN
Empyema Treated With tPA & DNAse
Lead Sponsor:
Children's Mercy Hospital Kansas City
Conditions:
Empyema
Eligibility:
All Genders
Up to 17 years
Phase:
PHASE3
Brief Summary
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit ...
Eligibility Criteria
Inclusion
- Patients less than 18 years of age requiring an intervention for empyema by one of the following:
- Septation or loculation seen on ultrasound or computed tomography or
- Greater than 10,000 white blood cells identified on pleural tap
Exclusion
- Immunodeficiency process
- Secondary diagnosis or condition that will keep them in the hospital beyond the empyema
- Existing contraindications to chest tube
- Documented allergy to one of the study medications
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01862458
Start Date
January 1 2016
End Date
January 1 2016
Last Update
January 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108